Rpo LLC Takes $37,000 Position in Senseonics Holdings, Inc. (NYSE:SENS)

Rpo LLC bought a new stake in shares of Senseonics Holdings, Inc. (NYSE:SENSFree Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 65,573 shares of the company’s stock, valued at approximately $37,000.

Separately, Ausdal Financial Partners Inc. grew its stake in Senseonics by 53.2% during the 3rd quarter. Ausdal Financial Partners Inc. now owns 72,000 shares of the company’s stock valued at $43,000 after acquiring an additional 25,000 shares in the last quarter. 12.36% of the stock is owned by institutional investors.

Senseonics Trading Down 0.9 %

Shares of SENS traded down $0.00 during trading on Wednesday, reaching $0.43. 442,191 shares of the company traded hands, compared to its average volume of 2,324,710. The stock has a 50-day simple moving average of $0.48 and a 200-day simple moving average of $0.56. The company has a quick ratio of 3.70, a current ratio of 3.96 and a debt-to-equity ratio of 1.79. Senseonics Holdings, Inc. has a twelve month low of $0.38 and a twelve month high of $1.05. The stock has a market cap of $228.97 million, a PE ratio of -3.11 and a beta of 0.91.

Senseonics (NYSE:SENSGet Free Report) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. Senseonics had a negative return on equity of 202.32% and a negative net margin of 346.38%. The business had revenue of $8.00 million during the quarter, compared to analysts’ expectations of $7.62 million. On average, analysts anticipate that Senseonics Holdings, Inc. will post -0.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Senseonics in a report on Friday, May 24th. They set a “sell” rating for the company.

View Our Latest Stock Report on SENS

Senseonics Company Profile

(Free Report)

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.

Recommended Stories

Institutional Ownership by Quarter for Senseonics (NYSE:SENS)

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.